NCT06600477View on ClinicalTrials.gov

A Study of Olanzapine After Intranasal and Intramuscular Administration

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

October 16, 2023

Primary Completion Date

November 1, 2023

Study Completion Date

November 1, 2023

Conditions

Healthy

Interventions

DRUG

olanzapine

7.5 mg

Trial Locations (1)

Unknown

International Pharmaceutical Research Center (IPRC) Clinical Site, Amman

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Neurelis, Inc.

INDUSTRY

NCT06600477 - A Study of Olanzapine After Intranasal and Intramuscular Administration | Biotech Hunter | Biotech Hunter